Advertisement

Breast Cancer Research and Treatment

, Volume 12, Issue 1, pp 81–82 | Cite as

Comment on ‘Difference between R5020 and the anti progestin RU486 in antiproliferative effects on human breast cancer cells’

  • M. R. Mooore
  • P. Gill
  • F. Vignon
  • H. Rochefort
Correspondence

Keywords

Public Health Breast Cancer Cancer Cell Breast Cancer Cell Human Breast Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hisson JR, Moore MR: Progestin effects on growth in the human breast cancer cell line T47D: possible therapeutic implications. Biochem Biophys Res Commun 145: 706–711, 1987PubMedGoogle Scholar
  2. 2.
    Manni A, Budger B, Wright C, Ahmed R, Demers LM: Effects of progestins on growth of experimental breast cancer in culture: interaction with estradiol and prolactin and involvement of the polyamine pathway. Cancer Res 47: 3066–3071, 1987PubMedGoogle Scholar
  3. 3.
    Robinson SP, Jordan VC: Reversal of the antitumor effects of tamoxifen by progesterone in the 7, 12-dimethylbenzan-thracene-induced rat mammary carcinoma model. Cancer Res 47: 5386–5390, 1987PubMedGoogle Scholar
  4. 4.
    Braunsberg H, Coldham NG, Leake RE, Wong W: Actions of a progestogen on human breast cancer cells: mechanisms of growth stimulation and inhibition. Eur J Cancer Clin Oncol 23: 563–571, 1987PubMedGoogle Scholar
  5. 5.
    Longman SM, Buehring GC: Oral contraceptives and breast cancer. In-vitro effect of contraceptive steroids on human mammary cell growth. Cancer 59: 281–287, 1987PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1988

Authors and Affiliations

  • M. R. Mooore
    • 1
  • P. Gill
    • 2
  • F. Vignon
    • 2
  • H. Rochefort
    • 2
  1. 1.Department of BiochemistryMarshall Univ. School of MedicineHuntingtonUSA
  2. 2.Inserm U 148MontpellierFrance

Personalised recommendations